SRX3207 is a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression with IC50 of 39.9 nM. SRX3207 demonstrates efficacy in multiple tumor models and represents a novel combinatorial approach to activate antitumor immunity. SRX3207 potently inhibited Syk and PI3K signaling and augmented the anti-tumor immune response in lung carcinoma tumor model with no toxicity.
CAS Number: 2254693-15-5
Molecular Weight: 555.65
Chemical Name: 3-[4-[[4-[4-(1-Azetidinylmethyl)-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]phenyl]-5-(4-morpholinyl)-7H-thieno[3, 2-b]pyran-7-one
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO: 33 mg/mL(59.38 mM)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
SRX3207 blocks both PI3K and Syk in MΦs thereby activating innate and adaptive antitumor immunity in vivo.
- Shweta Joshi, et al. Mol Cancer Ther . 2020 Mar;19(3):755-764.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.